Dr Elizabeth Stoner has over 30 years of experience in the life sciences sector. She has been involved in leading early-stage research through to the commercialisation of final products.
Boston-based Dr Stoner is the executive partner of MPM Capital, a leading US healthcare investment firm with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. She is also a clinical advisor to several of its portfolio companies including AlloVir and Rhythm Pharmaceuticals, and is the interim chief executive of cell therapy biotechnology company Semma Therapeutics which was acquired by Vertex in 2019 for US$950 million.
Prior to joining MPM Capital, Dr Stoner was the senior vice president of global clinical development operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries. While at Merck, she also oversaw the clinical development activities of its Japanese subsidiary and played a leading role in Merck/Schering Plough Joint Venture’s development of Vytorin and Zetia, blockbuster cholesterol lowering drugs. She had previously led the 5- alpha reductase clinical development program, establishing Merck as a leader in the field of prostate disease.
Prior to joining the biopharma industry, Dr Stoner was an Assistant Professor of Paediatrics at Cornell University Medical College.
She received her MD from the Albert Einstein College of Medicine.
